Business Context and Reporting Period
Company: Agenus Inc. (AGEN)
Filing Type: Form 8-K (Current Report)
Date of Report: October 08, 2025
Event: Entry into a Material Definitive Agreement (Promissory Note) with Zydus Pharmaceuticals (USA) Inc.
Key Financial Metrics and Transaction Details
- Principal Amount: Up to $10,000,000.
- Interest Rate: 3.81% per annum.
- Maturity: Upon closing of the Asset Purchase Agreement (APA) and Securities Purchase Agreement (SPA) signed on June 3, 2025, or within 10 days of notification that such closings will not occur.
- Collateral: 822,910 shares of MiNK Therapeutics, Inc. (INKT) common stock pledged by Agenus.
- Use of Proceeds: Funding operational expenses for Emeryville and Berkeley facilities for Q4 2025 and payments related to assets under the APA.
Material Changes and Terms
The filing discloses a new direct financial obligation. A critical feature of this agreement is the Forgiveness Feature: the portion of the proceeds used to fund operational expenses for the Emeryville and Berkeley facilities in Q4 2025 will be forgiven and not repaid if the APA/SPA transactions close. If the APA/SPA does not close, the note becomes due within 10 days of notification.
Guidance, Risks, and Contingencies
- Contingency: The repayment obligation is contingent on the failure of the APA/SPA closing. Successful closing triggers forgiveness of specific operational expense funding.
- Default Risk: Zydus holds a control agreement over the pledged MiNK Therapeutics shares, granting rights in the event of a default under the Note.
- Future Filings: Full text of the Note, pledge agreement, and control agreement (with confidential terms redacted) will be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2025.
Investor Verification Checklist
- Verify the status of the APA/SPA signed on June 3, 2025, to determine if the forgiveness feature will be triggered.
- Confirm the current market value and liquidity of the 822,910 MiNK Therapeutics (INKT) shares pledged as collateral.
- Review the upcoming Form 10-Q for the quarter ended September 30, 2025, for the full text of the Note and any redacted confidential terms.
- Assess the impact of the 3.81% interest rate on Agenus's cash flow if the APA/SPA fails to close.